The short version of actin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-02. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
===== Opioids ===== In humans addicted to opioids, epigenetic modifications of the OPRK1 gene, including altered DNA methylation profiles in peripheral blood cells, correlate with substance use severity and withdrawal symptoms.
== A priori therapeutic drug monitoring == A priori TDM consists of determining the initial dose regimen to be given to a patient, based on clinical endpoint and on established population pharmacokinetic–pharmacodynamic (PK/PD) relationships. These relationships help to identify sub-populations of patients with different dosage requirements, by utilizing demographic data, clinical findings, clinical chemistry results, and/or, when appropriate, pharmacogenetic characteristics.
Beta decays can be classified according to the angular momentum (L value) and total spin (S value) of the emitted radiation. Since total angular momentum must be conserved, including orbital and spin angular momentum, beta decay occurs by a variety of quantum state transitions to various nuclear angular momentum or spin states, known as "Fermi" or "Gamow–Teller" transitions. When beta decay particles carry no angular momentum (L = 0), the decay is referred to as "allowed", otherwise it is "forbidden". Other decay modes, which are rare, are known as bound state decay and double beta decay.
Sources: en.wikipedia.org
Anthropology & Education Quarterly. 13 (2): 133–148. doi:10.1525/aeq.1982.13.2.05x1830j. JSTOR 3216627. Spain, Victor; Scarlett, Janet; Houpt, Katherine (2004). "Long-term Risks and Benefits of Early-age Gonadectomy in Cats". Journal of the American Veterinary Medical Association. 224 (3): 372–379. doi:10.2460/javma.2004.224.372. PMID 14765796. Sturgess, Kit; Hurley, Karyl (2005). "Nutrition and Welfare". The Welfare of Cats. Animal Welfare. Vol. 3. Rochlitz. pp. 227–257. doi:10.1007/1-4020-3227-7_9. ISBN 1-4020-3226-9. Sunquist, Fiona; Sunquist, Mel (2014). The Wild Cat Book: Everything You Ever Wanted to Know About Cats. Chicago University. ISBN 978-0-226-14576-1. Tootle, John; Friedlander, Michael (1989). "Postnatal Development of the Spatial Contrast Sensitivity of X- and Y-cells in the Kittens Retinogeniculate Pathway". The Journal of Neuroscience. 9 (4). Journal of Neuroscience: 1325–1340. doi:10.1523/JNEUROSCI.09-04-01325.1989. PMC 6569875. PMID 2703879. Tsutsui, Toshihiko; Stabenfeldt, George (1993). "Biology of Ovarian Cycles, Pregnancy and Pseudo Pregnancy in the Domestic Cat". Journal of Reproduction and Fertility Supplement. 47: 29–35. PMID 8229938. Vandivert, Rita (1975). Understanding Animals as Pets. Illustrated Publishing. ISBN 978-0-7232-6118-6. Walls, Jerry (1991). Kittens as a New Pet. TFH Publications. ISBN 978-0-86622-614-1. Greco, D.S. (2014). Pediatric Nutrition. Veterinary Clinics of North America: Small Animal Practice. ISBN 978-0-32337-185-8.{{cite book}}: CS1 maint: publisher location (link)
=== Psychiatric problems === A significant risk involves extended difficulties and persistent mental health effects following the acute experience. A 2023 international survey found 14% of respondents felt more anxious for an extended period following ingestion. In one survey, 9% of users reported functional impairment lasting at least 24 hours beyond the trip itself. In another survey of 608 people reporting post-psychedelic difficulties, one third of the dataset said the difficulties lasted longer than a year, and one fifth said the difficulties lasted longer than three years. The most commonly-reported post-psychedelic difficulties in that study were anxiety, feeling traumatized by the experience or uncovering earlier trauma, social isolation, derealization/depersonalization, visual distortions and existential confusion. Rarely, psychedelics have been associated with suicide, including during acute intoxication.
The epithelial cells of the parathyroid glands are richly supplied with blood from the Inferior thyroid artery and superior thyroid artery. Parathyroid hormone acts on bone, the kidneys, and the GI tract to increase calcium reabsorption and phosphate excretion. In addition, it also stimulates the conversion of vitamin D to its most active variant, 1,25-dihydroxyvitamin D3, which further stimulates calcium absorption in the GI tract. The pancreas contains nearly 1 to 2 million pancreatic islets the organ's endocrine cells that secrete hormones, and acini. The acini secrete digestive enzymes. The pancreatic endocrine cells include alpha cells that produce and secrete the glucagon to maintain homeostatic blood sugar. In response to low blood sugar levels, the release of glucagon stimulates glycogen stores in the liver to release sugar into the bloodstream to raise blood sugar to normal levels. Pancreatic beta cells make up 60% of the cells in the islets. Along with alpha cells, beta cells help to maintain glucose levels in the body. In response to high blood sugar, beta cells secrete insulin, a hypoglycemic hormone. Insulin decreases blood glucose level by helping cells to take up and metabolize glucose, and by stopping the liver from releasing more glucose. Insulin also performs other metabolic functions: causing muscle cells to take up amino acids, and inhibiting the breakdown and release of fats. Delta cells (5%) in the islets produce regulatory somatostatin.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.